Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rubeshan Perumal

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Infection and Drug Resistance|June 13, 2023
Metformin Increases Cell Viability and Regulates Pro-Inflammatory Response to MtbNikita Naicker, Hylton Rodel, Rubeshan Perumal, et al.
BMJ Open|November 10, 2022
INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trialAnushka Naidoo, Kelly E Dooley, Kogieleum Naidoo, et al.
Eclinicalmedicine|April 1, 2025
High mortality among patients with tuberculosis accessing primary care facilities: secondary analysis from an open-label cluster-randomised trialKogieleum Naidoo, Nonhlanhla Yende Zuma, Mikaila Moodley, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|August 9, 2023
Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistanceSenamile Lale Ngema, Navisha Dookie, Rubeshan Perumal, et al.
Infection and Drug Resistance|December 21, 2023
Drug-Resistant TB, HIV and COVID-19 Co-Infection: Case Reviews from Kwa-Zulu Natal, South AfricaRazia Hassan-Moosa, Kegaugetswe Wilhemina Motsomi, Radhamoney Narasimmulu, et al.
BMC Immunology|August 31, 2023
Higher plasma interleukin - 6 levels are associated with lung cavitation in drug-resistant tuberculosisThando Glory Maseko, Slindile Ngubane, Marothi Letsoalo, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 3, 2022
The impact of enteral feeding and therapeutic monitoring of rifampicin with dose escalation in critically ill patients with tuberculosisRubeshan Perumal, Kogieleum Naidoo, Anushka Naidoo, et al.
BMC Infectious Diseases|March 25, 2026
Body mass index (BMI) at RR-TB diagnosis as an independent predictor of treatment outcomes: a retrospective analysisNonkululeko Mzinyane, Rubeshan Perumal, Lateef Babatunde Amusa, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2023
Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: an individual isolate metaanalysisCamus Nimmo, Neda Bionghi, Matthew J Cummings, et al.
Scientific Reports|July 20, 2023
NK cell phenotypic profile during active TB in people living with HIV-evolution during TB treatment and implications for bacterial clearance and disease severityThando Glory Maseko, Santhuri Rambaran, Slindile Ngubane, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Infection and Drug Resistance|June 13, 2023
Metformin Increases Cell Viability and Regulates Pro-Inflammatory Response to MtbNikita Naicker, Hylton Rodel, Rubeshan Perumal, et al.
BMJ Open|November 10, 2022
INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trialAnushka Naidoo, Kelly E Dooley, Kogieleum Naidoo, et al.
Eclinicalmedicine|April 1, 2025
High mortality among patients with tuberculosis accessing primary care facilities: secondary analysis from an open-label cluster-randomised trialKogieleum Naidoo, Nonhlanhla Yende Zuma, Mikaila Moodley, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|August 9, 2023
Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistanceSenamile Lale Ngema, Navisha Dookie, Rubeshan Perumal, et al.
Infection and Drug Resistance|December 21, 2023
Drug-Resistant TB, HIV and COVID-19 Co-Infection: Case Reviews from Kwa-Zulu Natal, South AfricaRazia Hassan-Moosa, Kegaugetswe Wilhemina Motsomi, Radhamoney Narasimmulu, et al.
BMC Immunology|August 31, 2023
Higher plasma interleukin - 6 levels are associated with lung cavitation in drug-resistant tuberculosisThando Glory Maseko, Slindile Ngubane, Marothi Letsoalo, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 3, 2022
The impact of enteral feeding and therapeutic monitoring of rifampicin with dose escalation in critically ill patients with tuberculosisRubeshan Perumal, Kogieleum Naidoo, Anushka Naidoo, et al.
BMC Infectious Diseases|March 25, 2026
Body mass index (BMI) at RR-TB diagnosis as an independent predictor of treatment outcomes: a retrospective analysisNonkululeko Mzinyane, Rubeshan Perumal, Lateef Babatunde Amusa, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2023
Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: an individual isolate metaanalysisCamus Nimmo, Neda Bionghi, Matthew J Cummings, et al.
Scientific Reports|July 20, 2023
NK cell phenotypic profile during active TB in people living with HIV-evolution during TB treatment and implications for bacterial clearance and disease severityThando Glory Maseko, Santhuri Rambaran, Slindile Ngubane, et al.
Pageof 6